Benzinga | Jun 4, 2021 08:31AM EDT

DarioHealth Releases Study Co Says Demonstrates Impact Of Personalized Digital Interventions To Improve Self-Management Of Diabetes

DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be presenting results of a new study at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021; June 2-5, 2021).

The study, titled "Impact of Digital Intervention Engine on Diabetes Self-Management," examined the effect of DarioHealth's highly personalized digital journeys on both clinical and engagement outcomes, applying user-specific digital intervention flows for behavioral change to increase user digital engagement.

This new research is a retrospective study of 246 DarioHealth users, and presents several meaningful outcomes achieved by the users:

* The percentage of users who measured blood glucose was significantly higher in the test group of 127 Dario users receiving interventions driven by the digital intervention engine: 14% in first 30 days and 22% in 30-60 days;

* The average number of blood glucose measurements increased by 6% and 17% at first 30 days and 30-60 days, respectively; and

* Recency (average number of days between blood glucose measurements) was significantly improved by 30% in the test group.

Most digital health solutions are personalized by applying generalized predictions across groups of "like" participants, not adapting to the truly unique needs of each participants. Dario's study found that personalizing the clinical interventions in response to unique individual circumstances, made possible by a powerful combination of AI, dynamically personalized user journeys, coaching, and behavior science, helps to durably improve self-monitoring and platform engagement among inconsistent users.

"The potential benefit of this research could be life-changing for so many people," said Dr. Yifat Hershcovitz, Ph.D., Scientific and Clinical Director at DarioHealth and one of the authors of the study. "In the context of busy day-to-day life, simply remembering to perform blood glucose measurements at meaningful intervals may be a challenge. The results of this study confirm that DarioHealth's platform and hyper-personalized approach makes it much easier for people to remember to incorporate measuring glucose levels into their everyday lives, improving and maintaining health outcomes."

"We believe that diabetes self-management is ripe for innovation, and our research illustrates the important role a digital intervention engine can play in helping people stay engaged in their diabetes management," said Dr. Omar Manejwala, Chief Medical Officer of DarioHealth. "DarioHealth is proud of our work to deliver a sustainable and impactful digital therapeutic solution, and these latest findings only add to our strong body of evidence that our hyper-personalized approach produces real, measurable improvements."



DarioHealth is presenting additional research at ATTD, titled "Impact of a Digital Therapeutic on Insulin Self-Management." For registration inquiries and additional information on ATTD 2021, visit ATTD.kenes.com. Attendance is welcomed and encouraged to all. Registration is discounted due to the conference being held virtually this year.